Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma



Status:Terminated
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 30
Updated:9/8/2018
Start Date:December 2011
End Date:December 2014

Use our guide to learn which trials are right for you!

A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and Medulloblastoma

The purpose of this research study is to evaluate a new investigational drug (TPI 287) for
neuroblastoma and medulloblastoma. An investigational drug is one that has not yet been
approved by the Food and Drug Administration. This investigational drug is called TPI 287.
This study will look at the tumor's response to the study drug, TPI 287, as well as the
safety and tolerability of the drug.

TPI 287 was shown to be effective in stopping tumor growth and was also shown to be safe in
three different animal species. TPI 287 has been tested in humans in four clinical trials,
and approximately 100 subjects with various types of cancers have received the drug,
including a pediatric population in our previous Phase I trial.


Inclusion Criteria:

- Subjects must have histologically proven neuroblastoma or medulloblastoma and
confirmation of refractory or recurrent disease with histologic confirmation at
diagnosis or at the time of recurrence/progression

- Subjects must be age >12 months and diagnosed before the age of 21

- Measurable disease, including at least one of the following:

- Measurable tumor >10mm by CT or MRI

- Positive bone marrow biopsy/aspirate.

- Positive MIBG

- Current disease state must be one for which there is currently no known curative
therapy

- Lansky Play Score or Karnofsky scale must be more than 30

- Subjects without bone marrow metastases must have an ANC > 750/μl and platelet count
>50,000/μl

- Adequate Renal Function Defined As

- Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or

- A serum creatinine based on age/gender

- Adequate liver function must be demonstrated, defined as:

- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age

- SGPT (ALT) < 10 x upper limit of normal (ULN) for age

- SGOT (AST) < 10x upper limit of normal (ULN) for age

- No other significant organ toxicity defined as > Grade 2 by National Cancer Institute
Common Toxicity Criteria for Adverse Events (NCI-CTCAE V4.0-
http://ctep.cancer.gov/forms/CTCAEv4.pdf)

- A negative urine pregnancy test is required for female participants of child bearing
potential (≥13 years of age or after onset of menses)

- Both male and female post-pubertal study subjects need to agree to use one of the more
effective birth control methods during treatment and for six months after treatment is
stopped. These methods include total abstinence (no sex), oral contraceptives ("the
pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or
medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be
used, contraceptive foam with a condom is recommended.

- Informed Consent: All subjects and/or legal guardians must sign informed written
consent. Assent, when appropriate, will be obtained according to institutional
guidelines

- Subjects may have received microtubulin inhibitors during previous therapies.

Exclusion Criteria:

- Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are
not eligible. Subjects must have fully recovered from the effects of prior
chemotherapy (hematological and bone marrow suppression effects), generally at least 3
weeks from the most recent administration (6 weeks for nitrosoureas).

- Subjects who have received any myeloablative therapy within the previous 2 months.

- Subjects receiving anti-tumor therapy for their disease or any investigational drug
concurrently

- Subjects with serious infection or a life-threatening illness (unrelated to tumor)
that is > Grade 2 (NCI CTCAE V4.0), or active, serious infections requiring parenteral
antibiotic therapy.

- Subjects with any other medical condition, including malabsorption syndromes, mental
illness or substance abuse, deemed by the Investigator to be likely to interfere with
the interpretation of the results or which would interfere with a patient's ability to
sign or the legal guardian's ability to sign the informed consent, and patient's
ability to cooperate and participate in the study

- Subjects with known hypersensitivity to any of the components of the drugs to be
administered on study
We found this trial at
8
sites
Hartford, Connecticut 06106
?
mi
from
Hartford, CT
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Kansas City, Missouri 64108
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Saint Louis, Missouri 63104
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials